<?xml version='1.0' encoding='utf-8'?>
<document id="25327846"><sentence text="Introduction of a nitrogen-containing side chain appended on C-10 of cethromycin leads to reduced CYP3A4 inhibition (WO2014049356A1)."><entity charOffset="18-26" id="DDI-PubMed.25327846.s1.e0" text="nitrogen" /><entity charOffset="69-80" id="DDI-PubMed.25327846.s1.e1" text="cethromycin" /><pair ddi="false" e1="DDI-PubMed.25327846.s1.e0" e2="DDI-PubMed.25327846.s1.e0" /><pair ddi="false" e1="DDI-PubMed.25327846.s1.e0" e2="DDI-PubMed.25327846.s1.e1" /></sentence><sentence text="Infections caused by antibiotic-resistant bacteria pose an increasing risk for clinical treatment" /><sentence text=" Macrolide-lincosamide-streptogramin B is becoming increasingly ineffective due to the methylation at the binding site of bacteria"><entity charOffset="23-38" id="DDI-PubMed.25327846.s3.e0" text="streptogramin B" /></sentence><sentence text=" Despite great efforts on the natural product, erythromycin, only one derivative, that is, telithromycin, capable of fighting against resistant bacteria has so far been marketed"><entity charOffset="47-59" id="DDI-PubMed.25327846.s4.e0" text="erythromycin" /><entity charOffset="91-104" id="DDI-PubMed.25327846.s4.e1" text="telithromycin" /><pair ddi="false" e1="DDI-PubMed.25327846.s4.e0" e2="DDI-PubMed.25327846.s4.e0" /><pair ddi="false" e1="DDI-PubMed.25327846.s4.e0" e2="DDI-PubMed.25327846.s4.e1" /></sentence><sentence text=" However, the 3'-dimethylamino group is readily metabolized to a nitroso group, which would inhibit CYP3A4, a very important metabolic enzyme responsible for nearly half of all marketed drugs"><entity charOffset="14-30" id="DDI-PubMed.25327846.s5.e0" text="3'-dimethylamino" /><entity charOffset="65-72" id="DDI-PubMed.25327846.s5.e1" text="nitroso" /><pair ddi="false" e1="DDI-PubMed.25327846.s5.e0" e2="DDI-PubMed.25327846.s5.e0" /><pair ddi="false" e1="DDI-PubMed.25327846.s5.e0" e2="DDI-PubMed.25327846.s5.e1" /></sentence><sentence text="" /><sentence text="Modifications at C-10 of erythromycin were seldom reported"><entity charOffset="25-37" id="DDI-PubMed.25327846.s7.e0" text="erythromycin" /></sentence><sentence text=" This invention disclosed novel ketolides that had a side chain comprising additional nitrogen atoms in place of the original 10-methyl group"><entity charOffset="32-41" id="DDI-PubMed.25327846.s8.e0" text="ketolides" /><entity charOffset="86-94" id="DDI-PubMed.25327846.s8.e1" text="nitrogen" /><entity charOffset="126-135" id="DDI-PubMed.25327846.s8.e2" text="10-methyl" /><pair ddi="false" e1="DDI-PubMed.25327846.s8.e0" e2="DDI-PubMed.25327846.s8.e0" /><pair ddi="false" e1="DDI-PubMed.25327846.s8.e0" e2="DDI-PubMed.25327846.s8.e1" /><pair ddi="false" e1="DDI-PubMed.25327846.s8.e0" e2="DDI-PubMed.25327846.s8.e2" /><pair ddi="false" e1="DDI-PubMed.25327846.s8.e1" e2="DDI-PubMed.25327846.s8.e1" /><pair ddi="false" e1="DDI-PubMed.25327846.s8.e1" e2="DDI-PubMed.25327846.s8.e2" /></sentence><sentence text=" Surprisingly, introduction of the side chain at C-10 led to reduced cytochrome inhibition and increased metabolic stability" /><sentence text=" As a result, the limited ability to inhibit CYP3A4 would relieve the drug-drug interaction and improve the safety of drug co-administration" /><sentence text="" /><sentence text="This invention opens a new avenue for future modifications to the erythromycin family"><entity charOffset="66-78" id="DDI-PubMed.25327846.s12.e0" text="erythromycin" /></sentence><sentence text=" It remains unclear how the side chain effected on reduction of CYP inhibition" /><sentence text=" To fully identify structure-activity relationships, the MIC data of the derivatives on gram-negative bacteria is desirable" /><sentence text="" /></document>